Similarly, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have shown efficacy in the treatment of coronary artery disease, and upregulation of PCSK9 has been identified in human CAVD and promotes VIC calcification in vitro (210). This evidence concerns the gene PCSK9 and congenital bilateral aplasia of vas deferens from CFTR mutation.